Jing Cai1 
,
Xue Xia2,
Jingmin Qiao1,
Ying Gao1,
Hongyan Li1,
Yiran Liu1
For correspondence:- Jing Cai Email: cj_dr11@163.com Tel:+8613633313283
Accepted: 28 February 2023 Published: 31 March 2023
Citation: Cai J, Xia X, Qiao J, Gao Y, Li H, Liu Y. Effect of Jinlida granule on glycolipid metabolism, oxidative stress, and inflammatory factors in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Trop J Pharm Res 2023; 22(3):597-603 doi: 10.4314/tjpr.v22i3.17
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the effect of Jinlida granule on glycolipid metabolism, oxidative stress, and inflammatory factors in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD).
Methods: A total of 132 T2DM patients with NAFLD were equally and randomly divided into study and control groups. Patients in the control group were treated with non-drug therapy including routine diet control, exercise, alcohol avoidance, and drug therapy (using blood glucose and lipid lowering drugs). The study group was treated with Jinlida granule in addition to other measures used in the control group. Blood glucose, blood lipid, and liver function parameters were compared after treatment. Nesfatin-1, oxidative stress, inflammatory factors, liver fat content, and degree of fibrosis were assessed. The efficacy and potential mechanism of Jinlida granule in the patients were assessed.
Results: Blood glucose, lipid, and liver function parameters in the study group were lower than in the control group following treatment. Nesfatin-1, GSH-Px, and adiponectin levels were higher, while MDA, TNF-α, liver fat, LSM and CAP levels were lower than in the control group (p < 0.05). The response rate of the study group was 96.97 %, which was higher than the 87.88 % in the control group (p < 0.05). The incidence of adverse drug reactions in the two groups during treatment was comparable (p > 0.05).
Conclusion: Jinlida granule exerts positive effect on T2DM patients with NAFLD. Thus, Jinlida granule has potentials for application as an adjuvant in the treatment of T2DM with NAFLD.
Archives
News Updates
Fulltext in PDF